查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2022-2029 年口腔黏膜炎全球市場
市場調查報告書
商品編碼
1140662

2022-2029 年口腔黏膜炎全球市場

Global Oral Mucositis Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

口腔黏膜炎市場規模預計在預測期間（2022-2029 年）將以 5.6% 的複合年增長率增長，高於 2021 年的 13.373 億美元。

口腔粘膜炎 (OM) 是口腔和咽喉粘膜的潰瘍或炎症。這是接受放射和化學療法治療頭頸癌的患者的常見副作用和嚴重並發症。大約 40% 的化療和所有放療患者會發展為口腔粘膜炎。嚴重的 OM 並發症包括極度疼痛和炎症、感染風險增加、營養不良、脫水、說話困難和藥物使用增加。如果不及時治療，這些瘡會導致危及生命的感染。口腔黏膜炎可通過多種測試診斷，包括活檢和真菌測試。用於治療 OM 的產品包括防腐漱口水、止痛劑、水溶性潤滑劑、鈍性漱口水和粘膜塗層。

市場動態

血液疾病的增加和技術進步是推動全球口腔粘膜炎市場的主要因素。

頭頸癌發病率的增加預計將推動市場增長。

美國和歐洲的 HNC 年發病率分別約為 150,000 和 750,000。據說這些患者中約有 60-70% 會發展為嚴重的口腔粘膜炎 (SOM)。口腔黏膜炎是由細胞毒化學治療劑對口腔黏膜的輻射效應和副作用引起的。美國國立衛生研究院估計，美國每年有超過 400,000 名患者被診斷出患有口腔粘膜炎。隨著全球癌症患者數量的增加，口腔黏膜炎治療藥物的市場也在不斷擴大。因此，口腔黏膜炎治療藥物的需求正在快速增長，預計將在預測期內推動市場增長。

此外，越來越多的臨床試驗和合作策略的採用正在加強口腔粘膜炎藥物的研發。截至 2019 年 3 月，口腔黏膜炎管線包括 20 多種處於不同開發階段的藥物（此外還有 9 種非處方藥）。 2020年6月，開發和商業化治療罕見疾病藥物的生物製藥公司Soligenix, Inc.宣布SGX942（dusquetide）用於治療頭頸癌（HNC）患者的口腔黏膜炎（OM）。完成了 3 期 DOM-INNATE 試驗的患者登記。註冊現已完成，預計將在 2020 年第四季度獲得一線結果。

口腔黏膜炎新藥開發的研究進展也有望在預測期內推動市場增長。例如，2020 年 5 月，亞利桑那大學藥學院的研究人員決定將以前用於治療非洲昏睡病的具有百年曆史的藥物蘇拉明重新用於對抗口腔粘膜炎和糖尿病足潰瘍。這一突破性的發展可以使成千上萬的患者受益，他們目前的治療對他們來說是部分有效的或痛苦的和侵入性的。

預計與口腔粘膜炎產品相關的嚴格審批將阻礙市場增長。

但是，以美國食品和藥物管理局 (USFDA)、歐洲藥品管理局 (EMA) 和美國國立衛生研究院 (NIH) 等監管機構授予和指定的形式，專利的頒發和長期嚴格的產品審批減緩了市場增長。

行業分析

全球口腔粘膜炎市場根據波特五力、監管和報銷分析、價值鏈分析、定價分析、供應鏈分析、未滿足的需求和流行病學等各種行業因素對市場進行了深入分析。

細分分析

預計致病部分將佔全球口腔粘膜炎市場的最大市場份額。

原因將全球口腔粘膜炎市場分為化療、放療和造血幹細胞移植。其中，化學療法引起的口腔粘膜炎預計將佔據很大的市場份額，因為化學療法被廣泛用作癌症的治療方法。例如，根據美國衛生與公眾服務部的數據，美國每年有超過 650,000 名癌症患者在腫瘤門診接受化療。口腔黏膜炎藥物市場包括冷凍療法、生長因子、抗氧化劑、抗炎劑、低水平激光療法（LLLT）、漱口水、阻隔劑和塗層等多種藥物配方和治療方法。批准用於治療口腔粘膜炎的藥物包括 Kepivance、GelX、NeutraSal、Easy 和 Caphosol。 2020年5月4日，美國WorldMeds推出了GELX ORAL GEL，這是一種鋅-牛磺酸生物活性屏障療法，可緩解口腔黏膜炎相關的口腔疼痛。 GELX ORAL GEL 是一種生物活性治療藥物，可在口腔粘膜炎中建立有效的抗疼痛和炎症屏障。提供針對口腔疼痛的生物防禦，並覆蓋暴露的神經末梢和開放性口腔炎。 GELX 通過提高藥物釋放率和溶解度的聚乙烯□咯烷酮遞送系統向粘膜環境提供一種生物活性的牛磺酸鋅複合物，該複合物已知可破壞和減緩口腔粘膜炎的炎症週期。 SGX942 (Soligenix, Inc.)、MuGard (Daewoong Pharmaceutical Co.)、CVXL-0095、Nu-3、Brilacidin 等正在研發中，預計將在預測期內進一步推動口腔黏膜炎治療市場。一項將 brilacidin 作為漱口水預防頭頸癌患者嚴重口腔粘膜炎 (SOM) 的 2 期試驗也達到了主要和次要終點，包括降低 SOM 的發生率。除了高未滿足的需求外，brilacidin 的初始價格是唯一的O.M.預期。我們的基線估計是，美國和歐洲的 brilacidin 漱口水市場每年將價值約 6 億美元至 12 億美元。

區域分析

北美地區在全球口腔粘膜炎市場中佔有最大的市場份額。

由於該地區慢性生活方式疾病的流行率不斷上升，北美在市場上佔據主導地位。它擁有最大的市場份額，主要是由於該國頭頸癌的患病率上升。例如，根據美國臨床腫瘤學會 (ASCO) 的數據，頭頸癌約占美國所有癌症的 4%。 2019 年，預計將有 65,410 人患上頭頸癌。

根據美國臨床腫瘤學會 (ASCO) 2021 年的一份報告，美國約有 4% 的人將患有頭頸癌，預計將有 66,630 人患頭頸癌。預計美國的高癌症病例將推動市場增長。

口腔黏膜炎每年在美國影響超過 500,000 人，代表了一個新市場，其中未滿足的醫療保健需求在很大程度上是一個長期存在的問題。根據美國疾病控制和預防中心的數據，美國每年約有 650,000 名癌症患者在門診接受化療，而共識是每年約有 500,000 名患者發生口腔粘膜炎。

此外，用於開發治療這種疾病的新產品的巨額資金和投資預計將推動美國市場的增長。例如，2020 年 6 月，Soligenix, Inc. 宣布完成 SGX942 (Daclyde) 治療頭頸癌 (HNC) 患者口腔黏膜炎 (OM) 的 3 期 DOM-INNATE 試驗的患者入組。

Galera Therapeutics, Inc. 宣佈在 2b 期臨床試驗中使用 Galera 的主要產品候選嚴重口腔粘膜炎 (SOM) 的頭頸癌患者的總體腫瘤病程 (GC4419) 進行了 2b 期臨床試驗，該試驗已於 2020 年 2 月披露。

競爭格局

口腔粘膜炎市場競爭激烈，由幾家主要參與者和新進入者組成。為市場增長做出貢獻的主要參與者包括 EUSA Pharma Inc.、Daewoong Pharmaceutical Co.、Soligenix, Inc.、Sunstar Suisse SA、Swedish Orphan Biovitrum Ltd.、Amgen Inc、Bausch Health、EKR Therapeutics, Inc. 包括 Access Pharmaceuticals, Inc、 Eisai Inc、Innovation Pharmaceuticals、Moberg Pharma AB 等。

值得關注的主要公司

Yusa Pharma Inc.

概述 EUSA Pharma Inc. 是一家全球專業製藥公司。該公司發現、製造和銷售特種藥品。該公司提供抗癌藥物、癌症治療支持、重症監護等。 EUSA Pharma 在全球銷售其產品。 EUSA Pharma 的臨床研發致力於改善我們產品的使用，以最大限度地提高癌症和罕見病患者的臨床利益。該公司是爵士製藥的子公司。

產品組合 Kafosol：批准用於治療和預防口腔黏膜炎，這是癌症治療（包括放療和化療）的副作用。含有高濃度的磷酸根離子和鈣離子，可潤滑口腔、舌頭和口咽部的黏膜，有助於保持口腔健康。 Cafosol 可作為安瓿或分散液使用。

我的實驗室 (TM) 9V

全球口腔粘膜炎市場報告提供了對大約 45 多個市場數據表、40 多個數字和 180 頁的訪問。

內容

第 1 章全球口腔黏膜炎市場研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章全球口腔黏膜炎市場 - 市場定義和概述

第 3 章全球口腔黏膜炎市場 - 執行摘要

  • 按原因劃分的市場細分
  • 按處理方法劃分的市場細分
  • 最終用戶的市場細分
  • 按地區劃分的市場細分

第 4 章全球口腔粘膜炎市場 - 市場動態

  • 市場影響因素
    • 驅動程序
      • 頭頸癌發病率增加
      • 增加研發投入
      • 在研藥物增加
    • 限制因素
      • 可供選擇的治療方法
    • 商機
    • 影響分析

第 5 章全球口腔黏膜炎市場 - 行業分析

  • 波特五力分析
  • 流行病學
  • 管道分析
  • 供應鏈分析
  • 定價分析
  • 監管分析
  • 未滿足的需求

第 6 章全球口腔黏膜炎市場 - 按原因

  • 化療
  • 放射治療
  • 造血幹細胞移植

第 7 章全球口腔黏膜炎市場 - 按治療方式

  • 漱口水
  • 成長因子
  • 低強度激光治療 (LLLT)
  • 冷凍療法
  • 其他

第 8 章全球口腔黏膜炎市場 - 按最終用戶分類

  • 醫院
  • 牙科診所
  • 腫瘤中心
  • 研究所
  • 其他

第 9 章全球口腔黏膜炎市場 - 按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 10 章全球口腔粘膜炎市場 - 競爭格局

  • 競爭場景
  • 市場情況/份額分析
  • 併購分析

第 11 章全球口腔黏膜炎市場 - 公司簡介

  • 大雄製藥
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • EUSA Pharma Inc.
  • Soligenix, Inc.
  • Sunstar Suisse SA
  • Swedish Orphan Biovitrum Ltd.
  • Amgen Inc.
  • Bausch Health
  • EKR Therapeutics, Inc.
  • Access Pharmaceuticals, Inc.
  • Eisai Inc.
  • BioAlliance Pharma SA.
  • Camurus AB
  • Moberg Pharma AB

第 12 章全球口腔黏膜炎市場 - 主要考慮因素

第 13 章全球口腔黏膜炎市場-主要考慮因素全球口腔黏膜炎市場-DataM

簡介目錄
Product Code: DMPH2587

Market Overview

The Oral Mucositis Market size was valued at US$ 1,337.30 million in 2021 and is estimated to reach US$ XX billion by 2029, growing at a CAGR of 5.6% during the forecast period (2022-2029).

Oral Mucositis (OM) is ulceration and inflammation of the mucosal membranes in the mouth and throat. It is a common side effect and serious complication for patients receiving radiation and chemotherapy with head and neck cancer treatments. About 40% of chemotherapy and all radiation patients develop oral mucositis. Serious OM complications include intolerable pain and inflammation, increased risk of infections, malnutrition, dehydration, difficulty speaking, and increased use of narcotics. If left untreated, these sores can lead to life-threatening infections. Oral mucositis is diagnosed through various tests, including biopsy and fungal testing. Antiseptic mouth rinses, pain killer medicines, water-soluble lubricating agents, bland rinses, and mucosal coating agents are some of the products used to treat OM.

Market Dynamics

Increase in hematological disorders and technological advancements are the major factors driving the global Oral Mucositis market.

Rising incidences of head and neck cancer are expected to drive market growth.

The annual incidence of HNC in the U.S. and Europe is approximately 150,000 and 750,000 cases globally. Approximately 60 to 70% of these patients will develop Severe Oral Mucositis (SOM). The side-effects of radiation effects and cytotoxic chemotherapy agents on oral mucosa lead to oral mucositis. As per the National Institutes of Health estimates, over 400,000 patients are diagnosed with oral mucositis annually in the United States. With the increasing prevalence of cancer patients globally, the market for oral mucositis therapeutics is also growing. Hence, the demand for oral mucositis treatment is rapidly growing, which is expected to drive market growth over the forecast period.

Besides, increasing clinical trials and the adoption of collaboration strategies are enhancing the oral mucositis therapeutics pipeline. As of March 2019, the oral mucositis therapeutics pipeline comprised more than twenty drugs (in addition to nine marketed drugs) in different development stages. In June 2020, Soligenix, Inc., a biopharmaceutical company developing and commercializing products to treat rare diseases, has completed patient enrollment in its Phase 3 DOM-INNATE study for SGX942 (dusquetide) for the treatment of oral mucositis (OM) in head and neck cancer (HNC) patients. With the enrollment completed, top-line results are expected in the fourth quarter of 2020.

Growing research to develop new drugs for oral mucositis is also expected to boost market growth during the forecast period. For instance, in May 2020, researchers at the University of Arizona College of Pharmacy have reformulated Suramin, a 100-yearold drug previously used to treat African sleeping sickness, to fight oral mucositis and diabetic foot ulcers. This breakthrough development can benefit thousands of patients whose current healing options are either partially effective or painful and invasive.

Stringent approvals associated with oral mucositis products is expected to hamper the market growth.

However, the issuance of patents and long stringent approvals for products in the form of grants and designations from regulatory bodies, including the U.S. Food and Drug Administration (USFDA), the European Medicines Agency (EMA), and the National Institutes of Health (NIH), among others is a slowing down the market growth.

Industry Analysis

The global oral mucositis market provides in-depth analysis of the market based on various industry factors such as porter's five forces, regulatory & reimbursement analysis, value chain analysis, pricing analysis, supply chain analysis, unmet needs, epidemiology etc.

Segment Analysis

Cause segment is expected to hold the largest market share in global oral mucositis market

Its cause segments the global oral mucositis market into chemotherapy, radiotherapy, and hematopoietic stem cell transplantation. Among these, the oral mucositis caused by the chemotherapy segment is expected to hold a major share in the market as chemotherapy is widely used as a treatment method for cancer. For instance, as per the U.S. Department of Health & Human Services, every year, more than 650,000 cancer patients receive chemotherapy in an outpatient oncology clinic in the U.S. The oral mucositis therapeutics market includes several kinds of drug formulations and treatments such as cryotherapy, growth factors, antioxidants, anti-inflammatory agents, low-level laser therapy (LLLT), mouthwashes, barriers, and coating agents. Some of the approved drugs for oral mucositis treatment include Kepivance, GelX, NeutraSal, Easy, and Caphosol. On May 4th, 2020, the U.S. WorldMeds, launched GELX ORAL GEL, a Zinc-Taurine bioactive barrier therapy for relief from oral pain associated with oral mucositis. GELX ORAL GEL is a bioactive therapy that can build an effective barrier against oral mucositis's pain and inflammation. It biomechanically protects against intraoral pain, coating exposed nerve endings and open sores. Through a polyvinylpyrrolidone delivery system, which can improve the release rate and solubility of drugs, GELX supplies the mucosal environment with a bioactive Zinc-Taurine Complex known to hinder and delay the inflammatory cycle of oral mucositis. SGX942 (Soligenix, Inc.), MuGard (Daewoong Pharmaceutical Co.), CVXL-0095, Nu-3, Brilacidin, among others, are in the pipeline, which is expected to further drive the oral mucositis therapeutics market over the forecast period. Also, A phase 2 trial of Brilacidin, as an oral rinse for preventing Severe Oral Mucositis (SOM) in patients with Head and Neck Cancer (HNC), met its primary and secondary endpoints, including reducing the incidence of SOM. The price for Brilacidin is anticipated at $5,000 to $10,000 per full course of treatment based on the large unmet need as well based on initial pricing for the only other O.M. drug ever approved (Palifermin, hematopoietic stem cell transplantation, HSCT). Based on the company's estimates, the total Brilacidin oral rinse market opportunity annually in the U.S. and Europe would be approximately $600 million to $1.2 billion.

Geographical Analysis

North America region holds the largest market share in the global oral mucositis market

North America is dominating the market due to increased prevalence of chronic lifestyle related diseases in the region. It accounts for the largest market share and is mainly attributed to the increasing prevalence of head and neck cancer in the country. For instance, according to the American Society of Clinical Oncology (ASCO), head and neck cancer account for about 4% of all cancers in the US. In 2019, an estimated 65,410 people will develop head and neck cancer.

According to the American Society of Clinical Oncology (ASCO)'s 2021 report, approximately 4% of individuals suffered from head and neck cancer in the U.S. and an estimate of 66,630 people were expected to develop head and neck cancer. High cases of cancer in the US is expected to drive market growth.

Oral mucositis affects over half a million people in the United States each year, and it provides a new market in which unmet health care needs are primarily intrinsically a long-standing problem. According to the Centers for Disease Control and Prevention, around 650,000 cancer patients get chemotherapy in an outpatient environment in the United States each year, and approximately 500,000 cases of oral mucositis occur in the United States each year, according to a consensus.

Moreover, huge funding and investments for the development of new products to treat the condition is expected to drive the market growth in the United States. Soligenix, Inc., for instance, announced in June 2020 that patient enrollment in its Phase 3 DOM-INNATE study for SGX942 (dusquetide) in the treatment of oral mucositis (OM) in patients with head and neck cancer (HNC) had been completed.

Galera Therapeutics, Inc. disclosed full tumour outcomes of patients with head and neck cancer treated with avasopasem manganese (GC4419), which is Galera's primary product candidate for severe oral mucositis (SOM) that was in a Phase 2b clinical trial, in February 2020.

Competitive Landscape

The oral mucositis market is highly competitive and consists of several major players and new players in the market. Some of the key players which are contributing to the growth of the market are EUSA Pharma Inc., Daewoong Pharmaceutical Co., Soligenix, Inc., Sunstar Suisse SA, Swedish Orphan Biovitrum Ltd., Amgen Inc., Bausch Health, EKR Therapeutics, Inc., Access Pharmaceuticals, Inc., Eisai Inc., Innovation Pharmaceuticals, Moberg Pharma AB, among others.

Key Companies to Watch

EUSA Pharma Inc:

Overview: EUSA Pharma Inc is a global speciality pharmaceutical company. The company creates, manufactures, and sells specialised pharmaceutical products. The company provides oncology drugs, oncology support, and critical care. EUSA Pharma sells its products all over the world. EUSA Pharma Clinical Research and Development is involved in improving the use of its products to maximize the clinical benefit for patients who have cancer or rare diseases. The company is a subsidiary of Jazz Pharmaceuticals.

Product Portfolio: Caphosol: It is approved for the treatment and prevention of oral mucositis, a side effect of cancer treatment (including radiation and chemotherapy). It contains a high concentration of phosphate and calcium ions, which lubricate the mucosa of the mouth, tongue, and oropharynx and aid in the preservation of the oral cavity's integrity. Caphosol is available in ampules or as a dispersible solution.

MyLab™9V

The global oral mucositis market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Global Oral Mucositis market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Oral Mucositis market - Market Definition and Overview

3. Global Oral Mucositis market - Executive Summary

  • 3.1. Market Snippet by Cause
  • 3.2. Market snippet by Treatment
  • 3.3. Market snippet by End-User
  • 3.4. Market Snippet by Region

4. Global Oral Mucositis market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing incidence of head & neck cancer
      • 4.1.1.2. Rising R&D investments
      • 4.1.1.3. Growing number of pipeline drugs
      • 4.1.1.4. XX
    • 4.1.2. Restraints:
      • 4.1.2.1. Availability of alternative treatment
      • 4.1.2.2. XX
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Oral Mucositis market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology
  • 5.3. Pipeline Analysis
  • 5.4. Supply Chain Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Unmet Needs

6. Global Oral Mucositis market - By Cause

  • 6.1. Introduction
  • 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cause Segment
  • 6.3. Market Attractiveness Index, By Cause Segment
    • 6.3.1. Chemotherapy*
      • 6.3.1.1. Introduction
      • 6.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 6.3.2. Radiotherapy
    • 6.3.3. Hematopoietic Stem Cell Transplantation

7. Global Oral Mucositis market - By Treatment

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 7.3. Market Attractiveness Index, By Treatment Segment
    • 7.3.1. Mouth Wash*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Growth Factors
    • 7.3.3. Low-level laser therapy (LLLT)
    • 7.3.4. Cryotherapy
    • 7.3.5. Others

8. Global Oral Mucositis market - By End-Users

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users Segment
  • 8.3. Market Attractiveness Index, By End-Users Segment
    • 8.3.1. Hospitals*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Dental Clinics
    • 8.3.3. Oncology Centers
    • 8.3.4. Research Institutes
    • 8.3.5. Others

9. Global Oral Mucositis market - By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cause
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cause
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Italy
      • 9.3.6.5. Spain
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cause
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cause
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. Australia
      • 9.5.6.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cause
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

10. Global Oral Mucositis market - Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Global Oral Mucositis market- Company Profiles

  • 11.1. Daewoong Pharmaceutical Co.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. EUSA Pharma Inc.
  • 11.3. Soligenix, Inc.
  • 11.4. Sunstar Suisse SA
  • 11.5. Swedish Orphan Biovitrum Ltd.
  • 11.6. Amgen Inc.
  • 11.7. Bausch Health
  • 11.8. EKR Therapeutics, Inc.
  • 11.9. Access Pharmaceuticals, Inc.
  • 11.10. Eisai Inc.
  • 11.11. BioAlliance Pharma SA.
  • 11.12. Camurus AB
  • 11.13. Moberg Pharma AB

LIST NOT EXHAUSTIVE

12. Global Oral Mucositis market - Premium Insights

13. Global Oral Mucositis market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us